Details for Patent: 8,648,097
Which drugs does patent 8,648,097 protect, and when does it expire?
Patent 8,648,097 protects OMLONTI and is included in one NDA.
This patent has twenty-three patent family members in seventeen countries.
Summary for Patent: 8,648,097
| Title: | Pyridylaminoacetic acid compound | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Abstract: | The present invention provides a novel pyridylaminoacetic acid compound represented by the following formula (1): (wherein R1, R2, R3, Y and Z are as defined in the description and claims), or a pharmacologically acceptable salt thereof. The pyridylaminoacetic acid compound has EP2 agonistic action and is therefore useful as a therapeutic and/or prophylactic agent for respiratory diseases such as asthma or chronic obstructive pulmonary disease. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Inventor(s): | Ryo Iwamura, Masayuki Tanaka, Tetsushi Katsube, Manabu Shigetomi, Eiji Okanari, Yasunori Tokunaga, Hiroshi Fujiwara | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Assignee: | Ube Corp | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Application Number: | US12/922,028 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Patent Claim Types: see list of patent claims | Composition; Compound; | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Patent landscape, scope, and claims: | United States Drug Patent 8,648,097: Claim Scope, Exclusivity, Litigation and Patent LandscapeU.S. Patent No. 8,648,097 protects a broad genus of pyridylaminoacetic acid compounds and their pharmacologically acceptable salts, with narrower claims directed to specific aryl-pyrazole and substituted pyridyl structures. Claim 15 extends protection to pharmaceutical compositions containing a claimed compound. The patent does not, from the supplied claims alone, identify an approved drug, an International Nonproprietary Name, an Orange Book-listed product, or a commercial licensee. The core commercial risk is compound-level infringement. A product may fall within the patent if it contains the claimed pyridylaminoacetic acid architecture, the specified sulfonylaminomethyl-linked aryl-pyrazole group, and a permitted pyridyl substitution pattern. The claims do not require a particular therapeutic indication, formulation, dosage strength, or manufacturing process. What does U.S. Patent 8,648,097 protect?The patent protects four related subject-matter categories:
Claim 1 is the principal genus claim. It covers compounds having:
The claims are composition-of-matter claims. They do not depend on a particular biological mechanism, disease indication or clinical use. What structural elements are required?The claim set requires the combination of several structural components rather than any isolated substituent:
The supplied claim language contains apparent drafting or transcription errors. Claim 5 states “wherein Y a -Q1-Q2 group,” claims 10 and 12 refer to “a 4 (pyrazol-1-yl)phenyl” rather than a fully punctuated structural definition, and claims 12 and 13 are substantively duplicated. The issued patent, its drawings and the prosecution history should control over a text transcription when assessing enforceability or infringement. How broad is independent claim 1?Claim 1 is materially broader than the later claims because it permits:
The claim does not require the preferred 4-(pyrazol-1-yl)phenyl arrangement. That narrower structure appears in claims 5, 6 and the later species claims. The claim also does not require a particular stereochemical configuration based on the supplied language. If the claimed molecular framework contains stereogenic centers, the absence or presence of an express stereochemical limitation would affect the reach of the claim and should be determined from the issued claim text and specification. What substituents are covered?The permitted substituents include:
Claim 6 enumerates particular pyrazolyl substituents, including methyl, ethyl, propyl, isopropyl, tert-butyl, trifluoromethyl, difluoromethyl, methoxy, ethoxy, tert-butoxy, trifluoromethoxy and related halogenated groups. Claims 7 and 9 narrow the Z pyridyl substituent to listed halogen, alkyl, alkoxy and halogenated groups. Claim 9 is particularly relevant to freedom-to-operate analysis because it limits Z to a pyridyl group substituted by a halogen or C1-C4 alkoxy group. What compounds are expressly covered by claim 14?Claim 14 identifies four compounds:
These species are narrower than the genus in claim 1 and are important for product-specific validity and infringement analysis. A commercial candidate matching one of these structures would face direct literal-claim exposure unless the claim is invalidated, disclaimed, expired or otherwise unenforceable. The claim 14 language also creates a construction issue. The named compounds contain a 4-(pyrazol-1-yl)benzyl group, while portions of claims 10-13 refer to a 4-(pyrazol-1-yl)phenyl group. The distinction between phenyl and benzyl is chemically material. The issued patent and prosecution record should be used to determine whether this reflects a transcription defect, an intentional distinction, or an antecedent structural definition elsewhere in the patent. How many patents cover the disclosed chemical series?Based on the supplied material, one U.S. patent is identified: U.S. Patent No. 8,648,097. The claim text alone does not establish whether related continuation, divisional, continuation-in-part, foreign, or terminal-disclaimer patents exist. A complete patent-family analysis would normally separate the following layers:
The supplied claims establish composition and pharmaceutical-composition protection. They do not establish separate formulation, method-of-use, polymorph, salt-selection or manufacturing claims. When does U.S. Patent 8,648,097 lose exclusivity?The patent number indicates issuance in 2014, but the expiration date cannot be calculated reliably from the claims alone. U.S. patent term generally depends on:
The relevant term is not normally measured from the 2014 issue date. A 20-year term is generally measured from the earliest effective U.S. nonprovisional filing date, subject to statutory adjustments. A definitive expiration date therefore requires the patent’s front page, priority chain and USPTO term data. Exclusivity timeline
A patent expiration date should not be inferred from the issuance date. The date controls generic-entry timing only after the patent family and statutory term are confirmed. What is the Orange Book status of U.S. Patent 8,648,097?No Orange Book status can be assigned from the supplied claim set because no approved drug product, active ingredient, New Drug Application holder or reference-listed drug is identified. The patent claims are directed to chemical compounds and a pharmaceutical composition. That type of claim can be eligible for Orange Book listing if it claims an approved drug substance, drug product or method of use and is properly submitted by an NDA holder. But patent eligibility for listing is product-specific. A compound patent is not automatically an Orange Book patent. For a generic applicant, the principal regulatory pathways would be:
No Paragraph IV challenge, ANDA, 30-month stay, Abbreviated New Drug Application litigation or settlement agreement is identified in the supplied record. What formulation patents are protected?Claim 15 is a broad pharmaceutical-composition claim. It covers a composition containing a claim 1 compound or salt and one or more conventional additives, including:
This is not a detailed dosage-form claim. It does not expressly require a tablet, capsule, injectable formulation, controlled-release matrix, enteric coating, nanoparticle, liposome, transdermal system or specific excipient ratio. Claim 15 may therefore be vulnerable to validity and construction challenges if read broadly against routine pharmaceutical formulation practice. Its practical value depends on the validity of claim 1 and whether the marketed composition contains a claimed compound or salt. It does not independently protect an unclaimed active ingredient merely because the product contains ordinary excipients. Are method-of-use patents or manufacturing patents covered?The supplied claims do not contain a method-of-use claim. There is no claim directed to:
The claims also do not define a synthetic process. They do not recite reaction conditions, starting materials, catalysts, solvents, purification steps or crystallization parameters. The principal barrier is therefore the active compound itself. An alternative manufacturing route would not avoid infringement if the resulting product falls within an asserted composition claim. Conversely, a process patent would be necessary to create a separate route-based barrier. How strong is the patent estate?The disclosed estate has moderate apparent breadth at the composition level, but its commercial strength cannot be ranked conclusively without the prosecution history and related-family claims. Strengths
Limiting factors
Potential invalidity pressure points would include prior-art compounds containing the same pyridylaminoacetic acid core, aryl-pyrazole linkage and sulfonylaminomethyl arrangement; genus breadth relative to the examples; and whether the specification enables the full range of substitutions recited in claim 1. Which companies are challenging the patent?No challenger, ANDA filer, district-court action, International Trade Commission investigation or settlement agreement is identified in the supplied material. A company developing a close analogue would face two distinct questions:
The most important design-around variables are the identity and attachment position of the pyridyl group, the arylene-pyrazolyl linkage, the sulfonylaminomethyl arrangement, and the substitution pattern around the aminoacetic acid portion. How does this patent affect generic and follow-on entry?This is not a conventional generic-entry case unless the claimed compound corresponds to an approved small-molecule drug. If no reference-listed drug exists, an ANDA strategy may not be available. A sponsor might instead pursue:
Biosimilar risk is not relevant to the patent as presented. The claims cover small-molecule chemical compounds, not a biologic, protein, antibody or biosimilar reference product. A biosimilar pathway under the Public Health Service Act would not ordinarily apply. What licensing and revenue exposure can be established?No licensing agreement, assignment, royalty arrangement, milestone package or collaboration is identified by the supplied claims. No revenue exposure can be calculated because the record does not identify:
The commercial value of the patent is therefore contingent on whether one of the claimed compounds became a clinical or commercial candidate. The patent alone does not establish product revenue. Key Takeaways
FAQsDoes U.S. Patent 8,648,097 claim a specific drug name?No drug name or International Nonproprietary Name appears in the supplied claims. The patent claims chemical structures and a pharmaceutical composition. Can a salt of a claimed compound avoid infringement?Not ordinarily if the salt is a pharmacologically acceptable salt covered by claim 1. The salt limitation is expressly included in the claims. Does claim 15 cover every tablet containing a pyridylaminoacetic acid compound?No. It requires a compound or salt within claim 1 and one or more listed pharmaceutical additives. It does not independently cover unrelated pyridylaminoacetic acid compounds. Is a 505(b)(2) application automatically blocked by this patent?No. Regulatory pathway and patent infringement are separate issues. A 505(b)(2) applicant would need to assess the specific active ingredient, listed patents and any applicable composition or use claims. Does the patent create biosimilar entry risk?No meaningful biosimilar risk is indicated. The claims concern small-molecule chemical compounds rather than biologic products. References
More… ↓ |
Drugs Protected by US Patent 8,648,097
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ocuvex Therap | OMLONTI | omidenepag isopropyl | SOLUTION;OPHTHALMIC | 215092-001 | Sep 22, 2022 | RX | Yes | Yes | 8,648,097 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,648,097
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2009224329 | ⤷ Start Trial | |||
| Canada | 2718393 | ⤷ Start Trial | |||
| China | 101970410 | ⤷ Start Trial | |||
| China | 103965099 | ⤷ Start Trial | |||
| Cyprus | 1121543 | ⤷ Start Trial | |||
| Denmark | 2264009 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
